Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
bPiDl hydrate may be used to study nicotinic receptor-mediated signaling.
Biochem/physiol Actions
bPiDI is an α6β2-specific antagonist that inhibits nicotine-evoked and endogenous dopamine release from rat striatal slices (IC50 = 150 nM, Imax = 55%). bPiDI treatment decreases nicotine self-administration, and nicotine-induced locomotor activity in rats.
Features and Benefits
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Packaging
10 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :